Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs.


Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
08 07 2020
Historique:
pubmed: 6 5 2020
medline: 6 5 2020
entrez: 6 5 2020
Statut: ppublish

Résumé

Proteolysis targeting chimeras (PROTACs) represent an exciting inhibitory modality with many advantages, including substoichiometric degradation of targets. Their scope, though, is still limited to date by the requirement for a sufficiently potent target binder. A solution that proved useful in tackling challenging targets is the use of electrophiles to allow irreversible binding to the target. However, such binding will negate the catalytic nature of PROTACs. Reversible covalent PROTACs potentially offer the best of both worlds. They possess the potency and selectivity associated with the formation of the covalent bond, while being able to dissociate and regenerate once the protein target is degraded. Using Bruton's tyrosine kinase (BTK) as a clinically relevant model system, we show efficient degradation by noncovalent, irreversible covalent, and reversible covalent PROTACs, with <10 nM DC

Identifiants

pubmed: 32369353
doi: 10.1021/jacs.9b13907
pmc: PMC7349657
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11734-11742

Commentaires et corrections

Type : ErratumIn

Références

Clin Cancer Res. 1999 Sep;5(9):2638-45
pubmed: 10499643
Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7285-E7292
pubmed: 30012605
Angew Chem Int Ed Engl. 2020 Apr 16;59(16):6342-6366
pubmed: 30869179
Nat Chem Biol. 2019 Mar;15(3):250-258
pubmed: 30643284
Chem Commun (Camb). 2019 Jan 17;55(7):929-932
pubmed: 30601480
ChemMedChem. 2007 Jan;2(1):58-61
pubmed: 17154430
Mol Biosyst. 2008 Sep;4(9):909-19
pubmed: 18704229
Nat Commun. 2019 Jan 10;10(1):131
pubmed: 30631068
Drug Discov Today Technol. 2019 Apr;31:15-27
pubmed: 31200855
Blood. 2019 Feb 28;133(9):952-961
pubmed: 30545835
ACS Chem Biol. 2019 Mar 15;14(3):361-368
pubmed: 30721025
Curr Opin Chem Biol. 2010 Jun;14(3):331-40
pubmed: 20395165
Angew Chem Int Ed Engl. 2016 Feb 5;55(6):1966-73
pubmed: 26756721
Nat Chem Biol. 2017 May;13(5):514-521
pubmed: 28288108
Biochemistry. 2018 Jul 3;57(26):3564-3575
pubmed: 29851337
ACS Chem Biol. 2018 Sep 21;13(9):2758-2770
pubmed: 30137962
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5
pubmed: 29129718
ACS Chem Biol. 2019 May 17;14(5):882-892
pubmed: 30978004
Chem Commun (Camb). 2020 Feb 4;56(10):1521-1524
pubmed: 31922153
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
pubmed: 20615965
Cell Chem Biol. 2018 Jan 18;25(1):67-77.e3
pubmed: 29129716
Nat Chem Biol. 2015 Jul;11(7):525-31
pubmed: 26006010
Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6
pubmed: 29129717
ACS Chem Biol. 2019 Mar 15;14(3):342-347
pubmed: 30807093
Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326
pubmed: 30802347
Mol Cancer. 2018 Feb 19;17(1):57
pubmed: 29455639
Nat Chem Biol. 2015 Aug;11(8):611-7
pubmed: 26075522
Nat Rev Drug Discov. 2019 Mar 6;:
pubmed: 30936511
ACS Chem Biol. 2015 Aug 21;10(8):1770-7
pubmed: 26035625
Cell Res. 2018 Jul;28(7):779-781
pubmed: 29875397
Cell Chem Biol. 2020 Jan 16;27(1):66-73.e7
pubmed: 31859249
Cell Chem Biol. 2019 Feb 21;26(2):300-306.e9
pubmed: 30595531
ACS Cent Sci. 2016 Dec 28;2(12):927-934
pubmed: 28058282
Chem Biol. 2014 Sep 18;21(9):1102-14
pubmed: 25237857
Nat Rev Cancer. 2014 Apr;14(4):219-32
pubmed: 24658273
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677
Nat Chem Biol. 2012 Apr 01;8(5):471-6
pubmed: 22466421
Bioorg Med Chem Lett. 2020 Feb 1;30(3):126877
pubmed: 31879210

Auteurs

Ronen Gabizon (R)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Amit Shraga (A)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Paul Gehrtz (P)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Ella Livnah (E)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Yamit Shorer (Y)

Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel.

Neta Gurwicz (N)

Department of Immunology, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Liat Avram (L)

Department of Chemical Research Support, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Tamar Unger (T)

Structural Proteomics Unit, Department of Life Sciences Core Facilities, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Hila Aharoni (H)

Structural Proteomics Unit, Department of Life Sciences Core Facilities, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Shira Albeck (S)

Structural Proteomics Unit, Department of Life Sciences Core Facilities, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Alexander Brandis (A)

Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel.

Ziv Shulman (Z)

Department of Immunology, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Ben-Zion Katz (BZ)

Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel.

Yair Herishanu (Y)

Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel.

Nir London (N)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 7610001, Israel.

Classifications MeSH